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LETTERS TO THE EDITOR
Improved Endothelial Function With
Metformin in Type 2 Diabetes Mellitus
Although the idea that metformin could improve endothelial
function in humans is not new (1), Mather et al. (2) are to be
congratulated in providing the first in vivo evidence that, in type 2
diabetic patients, metformin therapy for 12 weeks significantly
improved acetylcholine-stimulated, endothelium-dependent vaso-
dilation compared to placebo. They postulated potential mecha-
nisms for metformin’s beneficial effects (other than glucose-
lowering), including reduction in insulin resistance, antioxidant
effects, favorable effects on lipids and free fatty acids as well as
direct vasodilative effects (2). I would like to suggest an additional
mechanism that might have important clinical implications.
Over recent years, there is growing evidence that accumulation
of advanced glycation end products (AGEs) in hyperglycemic
states plays a dominant role in endothelial dysfunction, which
could lead to diabetic vasculopathy (3). Glycation is a nonenzy-
matic, posttranslational modification of protein, resulting from
chemical reactions between glucose and primary amino acids.
-Dicarbonyl molecules such as methylglyoxal (MG) and
3-deoxyglucosone are precursors of AGEs, which are increased in
diabetes. It has been shown that metformin reduces MG in vitro
(4). Similarly, in diabetic subjects treated with metformin, plasma
MG concentrations are significantly lower compared with those
treated with diet, sulfonylurea or insulin (5). This effect is
independent of glycemic control. This novel mechanism provides
the rationale of potential use of metformin (in addition to insulin)
to reduce vascular complications in type 1 diabetes. Large-scale
randomized control trials will be required to test this hypothesis.
Furthermore, other inhibitors of glycation, such as aminoguani-
dine, in conjunction with conventional antihyperglycemic treat-
ment for type 2 diabetes, may confer additional benefits in
reduction of vascular complications.
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REPLY
We appreciate Dr. Chan’s interest in our study, and we thank him
for pointing out this additional potential mechanism for the
beneficial effect of metformin in the vasculature. On the surface, it
may seem unlikely that changes in advanced glycosylation end
products (AGEs) would account for the findings in our study,
given both the relatively short duration of therapy and the
generally good glycemic control of our subjects at study entry
(HbAc  7%) (1).
However, as Dr. Chan correctly points out, favorable effects of
metformin on the levels of precursors of AGE such as methylg-
lyoxal have been noted (2,3). These intermediates have been
postulated to contribute to a state of “carbonyl stress” analogous to,
but distinct from, the oxidative stress engendered by AGEs acting
in part through specific cell-surface receptors for AGEs (4).
Although the dynamics of these intermediates are less clearly
understood than those of the end products, it is reasonable to
expect that such molecules are present in elevated concentrations in
proportion to ambient glycemia (3). Although AGEs have been
linked with impairments in endothelial function (5–7), no analo-
gous evidence documenting a relationship with the precursor
intermediates is available in the literature. Of course, these
intermediates have most likely been present in studies of hyper-
glycemia and endothelial function, including those specifically
addressing AGEs, and they may well have contributed to the
observed impairments in endothelial function. However, firm
connection remains to be established between carbonyl compounds
such as methylglyoxal and endothelial dysfunction.
Unfortunately, we were unable to quantitate either oxidative
stress or any of these carbonyl compounds in conjunction with our
therapy and cannot comment on the potential relationship to the
improved vascular function. As detailed in the Discussion section
of our paper (1), the mechanism of vascular benefit of metformin
in our study remains unexplained. We agree that this potential
mechanism for the vascular benefit of metformin warrants further
investigation and may be of relevance in both type 1 and type 2
diabetes mellitus.
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Absolute, Not Relative, Changes Are
Important When Interpreting Trial Data
Tsutamoto et al. (1) have recently reported on the beneficial effects
of spironolactone on plasma neurohormones and echocardio-
graphically derived left ventricular (LV) volume and mass indices
in patients with nonischemic congestive heart failure. Though
spironolactone is known to reduce morbidity and mortality in
severe heart failure, many of the mechanisms underlying these
effects have yet to be fully elucidated (2). Because aldosterone has
direct myocardial actions that may play an important role in LV
remodeling, it is particularly relevant to investigate the effects of
spironolactone on this process.
However, several points need careful consideration when inter-
preting the data presented by Tsutamoto et al. (1). First, the
investigators state that no significant differences existed between
the placebo- and spironolactone-treated groups at baseline. How-
ever, this seems somewhat surprising considering that the mean
baseline plasma-active renin concentration was 234 pg/ml in the
placebo group but only 93 pg/ml in the spironolactone group.
Furthermore, it appears that LV ejection fraction (LVEF) was
greater and both LV end diastolic volume and mass were lower in
the placebo group. Although these differences in echocardio-
graphic parameters did not reach significance, they have an
important bearing when interpreting the results after four months
of active therapy. The researchers concluded that spironolactone
treatment resulted in an improvement in indices of LV remodel-
ing, which was based upon a significant difference in changes of
echocardiographic parameters between the two groups at four
months. However, when determining the clinical relevance of a
novel therapy in any placebo-controlled study it is imperative to
compare the absolute means between the two groups at follow-up.
In our opinion, the investigators should have performed an
unpaired t test between the groups after four months of treatment.
As this has not been mentioned in the report by Tsutamoto et al.
(1), should we assume that these differences did not reach
statistical significance? This possibility is supported by the absolute
values given in the researchers Table 2 (1). For example, although
spironolactone therapy resulted in an increase in LVEF of 2.8%
(p  0.05), the absolute value of 35% after four months of
treatment was similar to that in the placebo group (baseline,
36.6%; four months, 36.3%). This demonstrates the potential
pitfalls of preenting relative changes as opposed to absolute values
in assessing the clinical benefits of a therapeutic agent.
One of the reasons that Tsutamoto et al. (1) were unable to
demonstrate a significant improvement in indices of LV remod-
eling (in terms of absolute values) may relate to the fact that the
measurements were made using echocardiography. This technique
is known to have poor reproducibility when applied to subjects
with impaired LV function. In contrast, cardiac magnetic reso-
nance imaging provides highly reproducible assessments of cardiac
volumes, function and mass in patients with heart failure (3). It is
especially important to use a technique with high reproducibility
when attempting to demonstrate significant differences using
relatively small numbers of participants, as was the case in the
study by Tsutamoto et al. (1).
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We appreciate the important remarks by Kalra et al. on our article
(1). We compared left ventricular (LV) volume and mass, as well
as plasma levels of atrial natriuretic peptide (ANP), brain natri-
uretic peptide (BNP) and procollagen type III aminoterminal
peptide (PIIINP), before and after treatment with spironolactone
or placebo. The LV volume and mass were significantly decreased
in the spironolactone group, but not in the placebo group. Plasma
levels of ANP, BNP and PIIINP were significantly decreased by
spironolactone, but did not change in the placebo group. A
significant positive correlation existed between the changes of
PIIINP and changes of the LV mass index with spironolactone
treatment. These findings indicate that four months of spirono-
lactone treatment improved LV volume and mass and decreased
the plasma level of BNP in nonischemic patients with congestive
heart failure (CHF).
In our study (1), to the evaluation of LV mass and LV function
in nonischemic CHF patients, we performed M-mode echocardi-
ography with two-dimensional (2-D) monitoring using a Sono-
layer phased-array sector scanner in a blinded fashion before and
after four months of treatment with spironolactone or placebo.
The LV volumes were calculated using Teichholtz’s formula, and
the LV ejection fraction was determined. The LV mass was
calculated using a method reported previously (2). An earlier study
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